首页> 美国卫生研究院文献>Cold Spring Harbor Molecular Case Studies >Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma
【2h】

Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma

机译:基因组学在确定复发性小儿甲状腺乳头状癌的治疗靶点中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Children with papillary thyroid carcinoma (PTC) may relapse despite response to radioactive iodine (RAI). Two children with multiply relapsed PTC underwent whole-genome and transcriptome sequencing. A TPM3-NTRK1 fusion was identified in one tumor, with outlier NTRK1 expression compared to the TCGA thyroid cancer compendium and to Illumina BodyMap normal thyroid. This patient demonstrated resolution of multiple pulmonary nodules without toxicity on oral TRK inhibitor therapy. A RET fusion was identified in the second tumor, another potentially actionable finding. Identification of oncogenic drivers in recurrent pediatric PTC may facilitate targeted therapy while avoiding repeated RAI.
机译:尽管对放射性碘(RAI)有反应,乳头状甲状腺癌(PTC)患儿仍可能复发。对两名患有多发性PTC的儿童进行了全基因组和转录组测序。在一个肿瘤中鉴定出TPM3-NTRK1融合体,与TCGA甲状腺癌汇编和Illumina BodyMap正常甲状腺相比,NTRK1表达异常。该患者表现出多种肺结节消退,对口服TRK抑制剂治疗无毒性。在第二个肿瘤中鉴定出RET融合,这是另一个可能起作用的发现。在复发性小儿PTC中确定致癌驱动因素可能有助于靶向治疗,同时避免重复进行RAI。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号